1. Recombinant interferon-α-2a for treatment of chronic hepatitis C: results of a multicenter randomized controlled dose study
- Author
-
H Maeda, F Kawakami, Kouichi Seki, Yuji Matsuzawa, Yoshinori Doi, Shinichi Kiso, Y. Imai, Y Minami, K Kiriyama, Shinichi Tamura, S Kawata, T Kashihara, S Himeno, M Nishiuchi, M Nishioka, Iwao Yabuuchi, Y. Shinji, Kazuto Fukuda, Nobuyuki Ito, Yasuhiro Shirai, Takumi Igura, and Toshifumi Ito
- Subjects
medicine.medical_specialty ,Dose ,medicine.medical_treatment ,Hepatitis C virus ,Alpha interferon ,Interferon alpha-2 ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,law.invention ,Flaviviridae ,Japan ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Humans ,Platelet ,Interferon alfa ,Hepatology ,biology ,business.industry ,Interferon-alpha ,Immunotherapy ,biology.organism_classification ,Hepatitis C ,Recombinant Proteins ,Treatment Outcome ,Chronic Disease ,Immunology ,business ,medicine.drug - Abstract
To compare the efficacy of low and relatively high dosages of recombinant interferon (IFN)-alpha-2a in Japanese patients with chronic hepatitis C, as well as to characterize the type of patients who will respond well to a low-dosage treatment, 88 patients with histologically proven chronic hepatitis C were randomly assigned to two treatment groups; one treated with IFN-alpha-2a 6 MU daily for 2 weeks followed by 6 MU three times weekly for 22 weeks (6-MU group), and another given the same initial treatment followed by 3 MU three times weekly for 22 weeks (3-MU group). The rate of sustained normalization of ALT 6 months after the cessation of treatment was 33% in the 3-MU group and 40% in the 6-MU group (p = 0.64). In addition, there was no difference in elimination of serum HCV-RNA 6 months after the cessation of treatment between the 3-MU group (26%) and 6-MU group (29%). Multivariate stepwise regression analysis revealed that serum HCV-RNA level (p = 0.0035) and platelet count (p = 0.0009) were independent variables useful in predicting a sustained response of ALT. The sustained response rate of ALT in patients with a serum HCV-RNA level less than 10(5) copies/ml and serum platelet level above 15 x 10(4)/microliter was 71%, whereas that in patients with a serum HCV-RNA level above 10(5) copies/ml and serum platelet level less than 15 x 10(4)/microliter was 12%. These results indicate that a high rate of sustained response to IFN therapy can be expected in chronic hepatitis C patients with a low serum level of HCV-RNA and a high level of platelets, even if treated with a low dose of IFN.
- Published
- 2008
- Full Text
- View/download PDF